ACOG has issued updated cervical cancer screening guidance that for the first time includes the option for patients aged 30 to 65 years at average risk to collect their own samples using FDA-approved testing kits for primary high-risk HPV (hrHPV) screening every three years.
The update, announced in an ACOG press release, aligns with recent recommendations from the Health Resources and Services Administration’s Women’s Preventive Services Initiative (WPSI). This change reflects growing evidence supporting self-collection as a viable method to expand access to screening, particularly for individuals facing barriers to in-office visits.
According to ACOG, clinicians should only offer self-collection if patients prefer this method and have access to appropriate follow-up systems. The organization emphasized that increasing screening access without established pathways for timely follow-up testing and treatment could delay diagnosis and prove detrimental to patients.
The updated guidance was highlighted in a statement from Steven J. Fleischman, MD, MBA, FACOG, president of the American College of Obstetricians & Gynecologists (ACOG), who noted a strong consensus in the medical community about improving access to cervical cancer screening. He pointed out that the United States is falling behind in screening rates, with too many people suffering from a largely preventable cancer.
Fleischman cited available data—mostly from outside the United States—supporting the efficacy of self-collection for primary high-risk HPV testing in certain populations. He referenced a recent study published in Obstetrics & Gynecology regarding patient preference, in which more than 70% of participants were open to the idea of self-collection.
ACOG acknowledged the potential of self-collected high-risk HPV testing to expand screening access but stressed that appropriate infrastructure must be in place to promptly connect individuals using at-home testing to follow-up testing and treatment when indicated.
The organization supports the new language in HRSA’s recommendation requiring no cost-sharing for any additional testing and pathologic evaluation needed as a result of initial screening findings. This ensures that patients who require further evaluation after a positive self-collected test are not burdened by out-of-pocket costs.
Self-collection for HPV testing involves patients using a swab or brush to collect a vaginal sample in a private setting, such as a clinic restroom or at home, which is then sent to a laboratory for analysis. FDA-approved kits for this purpose have demonstrated accuracy comparable to clinician-collected samples when used correctly.
Primary high-risk HPV screening detects the presence of HPV strains most strongly associated with cervical cancer development. Unlike Pap smears, which look for abnormal cell changes, HPV testing identifies the virus itself, allowing for earlier risk stratification.
The three-year screening interval for hrHPV testing in average-risk individuals aged 30 to 65 reflects evidence that persistent HPV infection—not transient exposure—is necessary for significant cervical precancer development. This interval balances early detection with minimizing unnecessary procedures.
ACOG’s update builds on prior WPSI recommendations that include screening for anxiety, urinary incontinence, intimate partner and domestic violence, obesity prevention in midlife women, contraception, well-woman visits, HIV, STI counseling, breast cancer screening, cervical cancer screening, breastfeeding services and diabetes screening during and after pregnancy.
The initiative aims to increase knowledge and usage of preventive service recommendations so more women receive comprehensive care without copayment, coinsurance, or deductible, thereby improving adult women’s health across their lifespan.
ACOG offers an enduring educational course titled “Recommendations for Women’s Preventive Health Care” that provides up to 2 AMA PRA Category 1 Credits™ for clinicians seeking to integrate WPSI guidelines into routine practice. The course covers the initiative’s methodology, resource access, and clinical application.
More information about WPSI and its resources is available at womenspreventivehealth.org, where the organization notes that its grant period ended on February 28, 2026, and it is transitioning to a new home on the ACOG Foundation page.
Recent publications supported by WPSI include a JABFM article on barriers and facilitators to screening for anxiety and intimate partner violence (February 2026), an Obstetrics & Gynecology piece on breast cancer screening expansion and patient navigation services, and a JAMA Internal Medicine study on how patient navigation improves screening efficacy across the breast cancer pathway.
These resources provide workflow diagrams, clinical summaries, and patient education tools designed to address real-world implementation challenges in preventive care settings.
As cervical cancer remains a significant global health concern—despite being largely preventable through vaccination and regular screening—expanding access through patient-preferred methods like self-collection represents a meaningful step toward equity in preventive health.
Healthcare systems interested in implementing self-collection options are advised to consult local regulatory requirements, ensure laboratory partnerships for timely processing, and establish clear protocols for patient notification and follow-up.
For the latest official updates on cervical cancer screening guidelines, patients and providers are encouraged to visit the ACOG website or consult the WPSI resource library directly.
We welcome your thoughts on this development. Share your experiences or questions in the comments below, and aid spread awareness by sharing this article with others who may benefit.